All In Biotech

Drug Trial Radar · NCT06502366

A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

A Randomized, Placebo-controlled, Double-blind, Multicenter, 12-Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared With BDA Delivered by MDI HFA in Participants With Asthma

Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 424 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

424

Actual

Start

Jul 22, 2024

Primary completion

Apr 17, 2026

Study completion Apr 17, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the PD equivalence of the approved asthma combination therapy, BDA, delivered using the proposed replacement propellant HFO compared with BDA delivered using the currently approved propellant HFA in participants with asthma.

Conditions

  • Asthma

Interventions

  • BDA MDI HFO 160/180 μgDrug

    Budesonide/albuterol pressurized inhalation suspension, HFO

  • BDA MDI HFA 160/180 μgDrug

    Budesonide/albuterol pressurized inhalation suspension, HFA

  • Placebo MDI HFADrug

    Placebo pressurized inhalation suspension, HFA

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in peak FEV1 in 0-60 minutes after dosing at Day 29Time frame: Change from baseline at Day 29
  2. Change from baseline in peak FEV1 in 0-60 minutes after dosing at Day 29Time frame: Change from baseline at Day 29

Locations

128 sites in 6 countries. Site status is shown where the registry gives one.

  • Research Site

    Mobile, Alabama

  • Research Site

    Sheffield, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Encinitas, California

  • Research Site

    Fullerton, California

  • Research Site

    Gardena, California

  • Research Site

    Huntington Beach, California

  • Research Site

    La Mesa, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Sacramento, California

  • Research Site

    San Bernardino, California

  • Research Site

    San Diego, California

  • Research Site

    San Jose, California

  • Research Site

    Santa Ana, California

  • Research Site

    Stockton, California

  • Research Site

    Westminster, California

  • Research Site

    Englewood, Colorado

  • Research Site

    Wheat Ridge, Colorado

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Boynton Beach, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Tallahassee, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Rincon, Georgia

  • Research Site

    Savannah, Georgia

  • Research Site

    Meridian, Idaho

  • Research Site

    River Forest, Illinois

  • Research Site

    Evansville, Indiana

  • Research Site

    Valparaiso, Indiana

  • Research Site

    Sioux City, Iowa

  • Research Site

    Louisville, Kentucky

  • Research Site

    Lafayette, Louisiana

  • Research Site

    New Orleans, Louisiana

  • Research Site

    White Marsh, Maryland

  • Research Site

    Flint, Michigan

  • Research Site

    Columbia, Missouri

  • Research Site

    St Louis, Missouri

Showing 40 of 128 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.